Stifel lowered the firm’s price target on Bio-Techne (TECH) to $60 from $75 and keeps a Hold rating on the shares. Growth is expected to step down to the low-single digit range in fiscal Q4, notes the analyst, who sees Bio-Techne as “somewhat caught between trying to lower expectations in a way that derisks the outlook while still signaling growth possibilities that can yield top-line differentiation.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue